Condition: Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma) · Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.
This description comes directly from the study's public registry record.
Mengli Zhou · 00-86-021-58953355 · mlzhou@fd-zj.com
Always discuss trial participation with your own doctor first.
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
| Shanghai East Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06424665